Merger & Acquisition
Five things for pharma marketers to know: Thursday, July 27, 2017
July 27, 2017Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug
Five things for pharma marketers to know: Thursday, July 20, 2017
July 20, 2017About 4.4 billion prescriptions filled in the U.S. in 2016; Sanofi and Ablynx reach I-O deal; biotech M&A slows in H1
Five things for pharma marketers to know: Thursday, June 29, 2017
June 29, 2017Walgreens ends merger with Rite Aid; Biogen hires former Novartis exec as SVP of corporate affairs; FDA takes new measures to drive drug pricing competition
Some brands thought to shift online ad dollars, creating uncertainty for WebMD
April 16, 2017This and other changes in the market have created demand for new offerings, like mobile-friendly sites, video, and patient communities.
WebMD considers sale or merger
February 17, 2017Drugmakers are becoming much more cautious with their budgets, WebMD executives said.
Five things for pharma marketers to know: Wednesday, February 15, 2017
February 15, 2017Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Five things for pharma marketers to know: Wednesday, August 3, 2016
August 03, 2016Merck and Allergan reportedly vying to buy Biogen; drugmakers fight California measure capping drug prices; few seniors use the web to look for health info
Five things for pharma marketers to know: Thursday, April 7, 2016
April 07, 2016Pfizer considers its options, post-Allergan deal; Allergan CEO says Treasury's rule-change was 'un-American;' IBM partners with Pfizer to study Parkinson's
WPP acquires CMI, retains minority stake in Compas
March 29, 2016WPP's acquisition of CMI, a significant player in the healthcare media-planning space, will likely bolster the services it provides to pharma clients.
Sudler & Hennessey acquires West Coast digital marketing firm
March 25, 2016Viscira, a digital marketing agency, works with GlaxoSmithKline, Merck, and Genentech, among other life-sciences companies.
Is This the End of Agency Diversification?
February 01, 2016DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.
Five things for pharma marketers to know: Wednesday, October 14, 2015
October 14, 2015J&J should pursue tuck-in deals; Lilly offers online college course about drug development; Clinton and Sanders identify drugmakers as political enemies
